Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 9/20 | 0.47 |
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26640996 | 0.85 | MAPKAPK2 (0.45) | MAPKAPK2ATRCYP17A1RORCMAP4K4 | |
| SCHEMBL1010435 | 0.83 | ATR (0.46) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL27576232 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL6497617 | 0.83 | MAPKAPK2 (0.41) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL31423753 | 0.81 | MAPKAPK2 (0.41) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL18805715 | 0.80 | RORC (0.53) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL18839612 | 0.80 | MAPKAPK2 (0.41) | MAPKAPK2ATRCYP17A1STK17BSTK17A | |
| SCHEMBL27576229 | 0.79 | LMNA (0.39) | MAPKAPK2ATRCYP17A1RORC | |
| SCHEMBL23147986 | 0.78 | ATF1 (0.42) | MAPKAPK2ATRRORCNAMPTMAP4K4 | |
| SCHEMBL29813512 | 0.78 | ATF1 (0.42) | MAPKAPK2ATRRORCNAMPTMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6890934-B2 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-09-11 | — | — | US | disclosed |
| US-6573274-B1 | Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| EP-1136492-A1 | SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171396-A1 | Sulfonamide compounds and uses thereof as medicines | PDE2A, PDE3A, PDE5A | MAPKAPK2 1363/4885ATR 2719/4885CYP17A1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.